Craig C. Hopkinson Sells 10,471 Shares of Alkermes plc (NASDAQ:ALKS) Stock

Alkermes plc (NASDAQ:ALKS) EVP Craig C. Hopkinson sold 10,471 shares of Alkermes stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $29.53, for a total transaction of $309,208.63. Following the completion of the transaction, the executive vice president now directly owns 99,238 shares of the company’s stock, valued at approximately $2,930,498.14. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Alkermes Price Performance

Shares of Alkermes stock opened at $28.97 on Friday. The company has a 50-day simple moving average of $27.65 and a two-hundred day simple moving average of $26.03. Alkermes plc has a twelve month low of $22.06 and a twelve month high of $32.88. The stock has a market capitalization of $4.69 billion, a price-to-earnings ratio of 14.86, a price-to-earnings-growth ratio of 0.89 and a beta of 0.47. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22.

Institutional Investors Weigh In On Alkermes

Institutional investors have recently made changes to their positions in the stock. Pathstone Holdings LLC raised its holdings in Alkermes by 72.8% in the 3rd quarter. Pathstone Holdings LLC now owns 71,324 shares of the company’s stock valued at $1,996,000 after acquiring an additional 30,048 shares in the last quarter. AMG National Trust Bank increased its position in shares of Alkermes by 68.3% in the third quarter. AMG National Trust Bank now owns 59,645 shares of the company’s stock worth $1,669,000 after purchasing an additional 24,200 shares during the period. Natixis Advisors LLC raised its stake in Alkermes by 190.3% in the third quarter. Natixis Advisors LLC now owns 36,490 shares of the company’s stock valued at $1,021,000 after purchasing an additional 23,921 shares in the last quarter. Nicollet Investment Management Inc. lifted its position in Alkermes by 1.7% during the third quarter. Nicollet Investment Management Inc. now owns 43,845 shares of the company’s stock worth $1,227,000 after purchasing an additional 714 shares during the period. Finally, Archer Investment Corp grew its stake in Alkermes by 28.6% during the third quarter. Archer Investment Corp now owns 4,500 shares of the company’s stock worth $126,000 after buying an additional 1,000 shares in the last quarter. 95.21% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on ALKS. HC Wainwright restated a “neutral” rating and issued a $37.00 price objective on shares of Alkermes in a research note on Friday, October 25th. Stifel Nicolaus raised Alkermes from a “hold” rating to a “buy” rating and boosted their target price for the stock from $25.00 to $36.00 in a report on Tuesday. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price target (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. The Goldman Sachs Group reduced their price objective on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.